Ciglitazone

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Cell permeable: no

Reversible: no

EC50 = 3 µM as PPARγ agonist

Product does not compete with ATP.

Primary TargetSelective PPARγ agonist

General description

A potent thiazolinedione (TDZ) type anti-hyperglycemic agent and a selective peroxisome proliferator-activated receptor γ (PPARγ) agonist (EC₅₀ = 3 µM).

A potent thiazolinedione (TDZ) type anti-hyperglycemic agent and a selective PPARγ agonist (EC₅₀ = 3 µM).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Jha, R.J. 1999. Clin. Exp. Hypertens. 21, 157.Xin, X., et al. 1999. J. Biol. Chem. 274, 9116.Lohrke, B., et al. 1998. J. Endocrinol. 159, 429.Willson, T.M., et al. 1996. J. Med. Chem. 39, 665.Cantello, B.C., et al. 1994. J. Med. Chem. 37, 3977.

Packaging

5 mg in Plastic ampoule

Reconstitution

Stock solutions are stable for up to 3 months at -20°C.

Warning

Toxicity: Harmful (C)